KR20150090091A - 볼라세르티브와의 병용 요법 - Google Patents
볼라세르티브와의 병용 요법 Download PDFInfo
- Publication number
- KR20150090091A KR20150090091A KR1020157014213A KR20157014213A KR20150090091A KR 20150090091 A KR20150090091 A KR 20150090091A KR 1020157014213 A KR1020157014213 A KR 1020157014213A KR 20157014213 A KR20157014213 A KR 20157014213A KR 20150090091 A KR20150090091 A KR 20150090091A
- Authority
- KR
- South Korea
- Prior art keywords
- aml
- days
- effective amount
- surface area
- body surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002648 combination therapy Methods 0.000 title description 10
- SXNJFOWDRLKDSF-STROYTFGSA-N volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 title 1
- 229950003081 volasertib Drugs 0.000 title 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 114
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 113
- 238000011282 treatment Methods 0.000 claims abstract description 48
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims abstract description 29
- 229960000684 cytarabine Drugs 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims abstract description 14
- VNTHYLVDGVBPOU-QQYBVWGSSA-N (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 VNTHYLVDGVBPOU-QQYBVWGSSA-N 0.000 claims abstract description 13
- 229960000390 fludarabine Drugs 0.000 claims abstract description 13
- 238000002347 injection Methods 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 229940052372 daunorubicin citrate liposome Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 6
- 230000001737 promoting effect Effects 0.000 claims 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 abstract description 33
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 abstract description 31
- 229960003334 daunorubicin citrate Drugs 0.000 abstract description 8
- 210000003714 granulocyte Anatomy 0.000 abstract description 4
- 208000032839 leukemia Diseases 0.000 description 19
- 239000003814 drug Substances 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 201000010374 Down Syndrome Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 101100114967 Homo sapiens CSF3 gene Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000010581 Acute myeloid leukemia with minimal differentiation Diseases 0.000 description 2
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 2
- 206010008583 Chloroma Diseases 0.000 description 2
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 2
- 102000008147 Core Binding Factor beta Subunit Human genes 0.000 description 2
- 108010060313 Core Binding Factor beta Subunit Proteins 0.000 description 2
- 102100034583 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 Human genes 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 102100039121 Histone-lysine N-methyltransferase MECOM Human genes 0.000 description 2
- 101000590272 Homo sapiens 26S proteasome non-ATPase regulatory subunit 2 Proteins 0.000 description 2
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 2
- 101000848781 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 Proteins 0.000 description 2
- 101001033728 Homo sapiens Histone-lysine N-methyltransferase MECOM Proteins 0.000 description 2
- 101000591286 Homo sapiens Myocardin-related transcription factor A Proteins 0.000 description 2
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 2
- 101000996563 Homo sapiens Nuclear pore complex protein Nup214 Proteins 0.000 description 2
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 2
- 101000959489 Homo sapiens Protein AF-9 Proteins 0.000 description 2
- 101001062093 Homo sapiens RNA-binding protein 15 Proteins 0.000 description 2
- 101100078258 Homo sapiens RUNX1T1 gene Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 102100034099 Myocardin-related transcription factor A Human genes 0.000 description 2
- 102100036639 Myosin-11 Human genes 0.000 description 2
- 102100033819 Nuclear pore complex protein Nup214 Human genes 0.000 description 2
- 102100022678 Nucleophosmin Human genes 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102100039686 Protein AF-9 Human genes 0.000 description 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 2
- 102100029244 RNA-binding protein 15 Human genes 0.000 description 2
- 108700040655 RUNX1 Translocation Partner 1 Proteins 0.000 description 2
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000005861 gene abnormality Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 201000005987 myeloid sarcoma Diseases 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 108010056274 polo-like kinase 1 Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 208000003476 primary myelofibrosis Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000009517 secondary packaging Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- WEVWMDXKENHVCZ-UHFFFAOYSA-N 3,4-dihydro-1h-pteridin-2-one Chemical class C1=CN=C2NC(=O)NCC2=N1 WEVWMDXKENHVCZ-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-STUHELBRSA-N 4-amino-1-[(3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-STUHELBRSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101001092185 Homo sapiens Regulator of cell cycle RGCC Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102100035542 Regulator of cell cycle RGCC Human genes 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229940107841 daunoxome Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195162.8 | 2012-11-30 | ||
| EP12195162 | 2012-11-30 | ||
| PCT/EP2013/074862 WO2014083058A1 (en) | 2012-11-30 | 2013-11-27 | Combination therapy with volasertib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150090091A true KR20150090091A (ko) | 2015-08-05 |
Family
ID=47325907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157014213A Withdrawn KR20150090091A (ko) | 2012-11-30 | 2013-11-27 | 볼라세르티브와의 병용 요법 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20140154304A1 (OSRAM) |
| EP (1) | EP2925343A1 (OSRAM) |
| JP (1) | JP2016501208A (OSRAM) |
| KR (1) | KR20150090091A (OSRAM) |
| CN (1) | CN104812400A (OSRAM) |
| AU (1) | AU2013351180A1 (OSRAM) |
| BR (1) | BR112015011748A2 (OSRAM) |
| CA (1) | CA2889787A1 (OSRAM) |
| CL (1) | CL2015001258A1 (OSRAM) |
| EA (1) | EA201500579A1 (OSRAM) |
| IL (1) | IL238174A0 (OSRAM) |
| IN (1) | IN2015DN03075A (OSRAM) |
| MX (1) | MX2015006592A (OSRAM) |
| PH (1) | PH12015501113A1 (OSRAM) |
| WO (1) | WO2014083058A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9867831B2 (en) * | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| CN104306336B (zh) * | 2014-11-18 | 2016-08-24 | 河北天成药业股份有限公司 | 枸橼酸柔红霉素脂质体注射液的制备工艺 |
| HK1258724A1 (zh) * | 2015-11-11 | 2019-11-15 | Celator Pharmaceuticals, Inc. | 选择白血病对象的治疗方案的分析和方法 |
| US20230201202A1 (en) * | 2020-05-27 | 2023-06-29 | Duke University | Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy |
| CN116785296B (zh) * | 2023-06-06 | 2025-09-05 | 河北渤腾医药技术有限公司 | 一种plk1的抑制剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2517020C (en) | 2003-02-26 | 2012-06-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, method for the production and use thereof in the form of drugs |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US20100136029A1 (en) * | 2006-12-20 | 2010-06-03 | Universitatsklinikum Hamburg-Eppendorf | Use of Tri-Substituted Glycerol Compounds for the Treatment of Hematological Malignancies |
| AU2008216083B2 (en) * | 2007-02-16 | 2014-02-06 | Jazz Pharmaceuticals Therapeutics, Inc. | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
| US9358233B2 (en) * | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
-
2013
- 2013-11-25 US US14/088,948 patent/US20140154304A1/en not_active Abandoned
- 2013-11-27 CN CN201380062203.7A patent/CN104812400A/zh active Pending
- 2013-11-27 MX MX2015006592A patent/MX2015006592A/es unknown
- 2013-11-27 KR KR1020157014213A patent/KR20150090091A/ko not_active Withdrawn
- 2013-11-27 BR BR112015011748A patent/BR112015011748A2/pt not_active IP Right Cessation
- 2013-11-27 AU AU2013351180A patent/AU2013351180A1/en not_active Abandoned
- 2013-11-27 CA CA2889787A patent/CA2889787A1/en not_active Abandoned
- 2013-11-27 WO PCT/EP2013/074862 patent/WO2014083058A1/en not_active Ceased
- 2013-11-27 EA EA201500579A patent/EA201500579A1/ru unknown
- 2013-11-27 JP JP2015544453A patent/JP2016501208A/ja active Pending
- 2013-11-27 EP EP13795533.2A patent/EP2925343A1/en not_active Withdrawn
-
2015
- 2015-04-12 IL IL238174A patent/IL238174A0/en unknown
- 2015-04-13 IN IN3075DEN2015 patent/IN2015DN03075A/en unknown
- 2015-05-11 CL CL2015001258A patent/CL2015001258A1/es unknown
- 2015-05-20 PH PH12015501113A patent/PH12015501113A1/en unknown
-
2017
- 2017-03-03 US US15/448,660 patent/US20170173023A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104812400A (zh) | 2015-07-29 |
| JP2016501208A (ja) | 2016-01-18 |
| MX2015006592A (es) | 2015-08-05 |
| WO2014083058A1 (en) | 2014-06-05 |
| US20140154304A1 (en) | 2014-06-05 |
| US20170173023A1 (en) | 2017-06-22 |
| EP2925343A1 (en) | 2015-10-07 |
| IN2015DN03075A (OSRAM) | 2015-10-02 |
| CL2015001258A1 (es) | 2015-10-02 |
| PH12015501113A1 (en) | 2015-08-17 |
| CA2889787A1 (en) | 2014-06-05 |
| IL238174A0 (en) | 2015-05-31 |
| BR112015011748A2 (pt) | 2017-07-11 |
| AU2013351180A1 (en) | 2015-04-30 |
| EA201500579A1 (ru) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9358233B2 (en) | Method for treating acute myeloid leukemia | |
| US9205098B2 (en) | Anti-cancer therapies | |
| WO2019109074A1 (en) | Mebendazole cancer therapies and methods of use | |
| US20170173023A1 (en) | Combination therapy with volasertib | |
| CN113164502A (zh) | 血液病的低强度治疗 | |
| EP2928456B1 (en) | Treatment of hematological cancer refractory to an anti-cancer agent | |
| EP3407887A1 (en) | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| JP5317987B2 (ja) | 白血病の治療のための新規な治療のための使用 | |
| EP4197539A1 (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma | |
| JP2023512724A (ja) | リンパ腫の治療におけるピリド［１，２－ａ］ピリミジノン化合物の使用 | |
| JP2023509191A (ja) | 癌を治療するための組み合わせ療法 | |
| US20190240242A1 (en) | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii | |
| EP3200879B1 (en) | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome iii | |
| KR20160037233A (ko) | 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브 | |
| CN114984015A (zh) | 治疗增殖性疾病的联用药物组合物 | |
| EP4188387A1 (en) | Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof | |
| HK40092504A (zh) | 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物 | |
| CA3217214A1 (en) | Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)- 2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1- oxoisoindoline-5-carboxamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150528 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |